Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

Using inflammation to advance precision treatment of refractory depression

EF 2025-26

Résumé
Many people with clinical depression do not benefit from antidepressant medications and are diagnosed with treatment resistant depression (TRD). Recent research shows that inflammation in the body may play a role in TRD, suggesting that some patients might benefit from anti-inflammatory treatments. Early studies have shown that the anti-inflammatory medication minocycline may improve depressive symptoms in TRD, especially in people with high levels of inflammation. The objectives of this research are to determine whether minocycline added to antidepressants for 12 weeks can safely reduce depressive symptoms in adults with TRD, and to investigate whether biological and clinical indicators of inflammation can predict minocycline response. I hypothesize that TRD patients who receive minocycline added to antidepressants will show greater reductions in depression than those who receive placebo, with no difference in side effects. My exploratory hypotheses predict that patients with higher inflammatory characteristics at baseline will show greater reductions in depression and that depressive changes will depend on change in biological markers of inflammation. 100 adults with TRD from the Centre for Addiction and Mental Health (CAMH) will be randomly assigned to receive minocycline or placebo added to antidepressant medications for 12 weeks. Neither patients nor researchers know which add-on treatment is given. I will measure changes in depression using scores on the Hamilton Depression Rating Scale (HDRS-17). Blood samples taken throughout treatment will be analyzed to examine changes in inflammatory markers. Findings may reveal a safe and effective new treatment for TRD, reducing patient suffering and healthcare needs. If I can identify clinical and biological markers (i.e. "biomarkers") of minocycline response, future studies could use these indicators to easily identify patients with inflammatory TRD and increase precision of anti-inflammatory treatment strategies.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559655
Name
Kittur Mary E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Using inflammation to advance precision treatment of refractory depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Anti-Inflammatory Treatment; Inflammatory Biomarkers; Precision Psychiatry; Randomized Clinical Trial (Rct); Treatment-Resistant Depression (Trd)
Abstract
Many people with clinical depression do not benefit from antidepressant medications and are diagnosed with treatment resistant depression (TRD). Recent research shows that inflammation in the body may play a role in TRD, suggesting that some patients might benefit from anti-inflammatory treatments. Early studies have shown that the anti-inflammatory medication minocycline may improve depressive symptoms in TRD, especially in people with high levels of inflammation. The objectives of this research are to determine whether minocycline added to antidepressants for 12 weeks can safely reduce depressive symptoms in adults with TRD, and to investigate whether biological and clinical indicators of inflammation can predict minocycline response. I hypothesize that TRD patients who receive minocycline added to antidepressants will show greater reductions in depression than those who receive placebo, with no difference in side effects. My exploratory hypotheses predict that patients with higher inflammatory characteristics at baseline will show greater reductions in depression and that depressive changes will depend on change in biological markers of inflammation. 100 adults with TRD from the Centre for Addiction and Mental Health (CAMH) will be randomly assigned to receive minocycline or placebo added to antidepressant medications for 12 weeks. Neither patients nor researchers know which add-on treatment is given. I will measure changes in depression using scores on the Hamilton Depression Rating Scale (HDRS-17). Blood samples taken throughout treatment will be analyzed to examine changes in inflammatory markers. Findings may reveal a safe and effective new treatment for TRD, reducing patient suffering and healthcare needs. If I can identify clinical and biological markers (i.e. "biomarkers") of minocycline response, future studies could use these indicators to easily identify patients with inflammatory TRD and increase precision of anti-inflammatory treatment strategies.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kittur, Mary E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~